The vaccine, mycobacterium indicus pranii (MIP), will be administered as prevention for people living in close contact with those infected by the bacteria. “It is the first vaccine for leprosy, and India will be the first to have a large-scale vaccination programme.
Trials have shown that if the vaccine is given to people in close contact with the affected, cases can be brought down by 60% in three years. It expedites cure rate if given to people with skin lesions,” said Indian Council of Medical Research director general Dr Soumya Swaminathan.
The vaccine developed by founder-director of the National Institute of Immunology(NII) G P Talwar, has been approved by the Drug Controller General of India (DCGI) and the US-FDA.
Source Indian news